Résumé
Objective:To investigate therapeutic effect of cisplatin sequential recombinant human vascular endostatin thoracic perfusion in treatment of malignant pleural effusion.Methods:A total of 80 patients with malignant pleural effusion in Maoming People's Hospital from January 2018 to February 2021 were enrolled, and all patients were divided into 2 groups according to the random number table methods, each group with 40 cases. The control group was treated with small-bore catheter minimally invasive drainage combined with cisplatin thoracic perfusion, and the study group was treated with small-bore catheter minimally invasive drainage combined with cisplatin sequential recombinant human vascular endostatin thoracic perfusion. And then the clinical efficacy, expressions of vascular endothelial growth factor (VEGF) expression, pain degree and adverse reactions were compared of both groups.Results:The treatment efficacy rate of the study group was higher than that of the control group [90% (36/40) vs. 75% (30/40)], and the difference was statistically significant ( χ2 = 5.04, P < 0.05). After treatment, the level of VEGF in pleural fluid and serum of the study group was lower than that of the control group [(304±106) pg/ml vs. (598±159) pg/ml,(103±43) pg/ml vs. (189±49) pg/ml], and the difference was statistically significant ( t = 6.62, P < 0.001; t = 6.23, P < 0.001). After treatment, the visual analogue scale (VAS) score of the study group was lower than that of the control group [(3.7±0.3) scores vs. (4.4±0.7) scores], and the difference was statistically significant ( t = 2.10, P < 0.05). The incidence of adverse reactions including stethalgia, fever, nausea and vomiting in both groups had no statistically significant differences (all P > 0.05). Conclusions:Cisplatin sequential recombinant human vascular endostatin thoracic perfusion combined with small-bore catheter minimally invasive drainage can effectively ameliorate clinical symptoms, inhibit the expression of VEGF, and alleviate pain degree with no serious adverse reactions in patients with malignant pleural effusion.
Résumé
Objective To investigate the application value of the combined detection of the serum levels of tumor-associated car-bohydrate antigen 125(CA125) and human epididymis epithelial secretory protein 4 (HE4) in the diagnosis and the differentiation diagnosis of ovarian cancer .Methods Serum levels of CA125 and HE4 in 51 patients with ovarian cancer ,37 patients with benign ovarian tumor and 40 healthy females as the healthy control group were measured by chemiluminescent immunoassay (CLIA) and enzyme linked immunosorbent assay(ELISA) respectively .The detection results combined with the clinical data were performed the statistical analysis .Results The serum levels of CA125 and HE4 in the ovarian cancer group were significantly higher than those in the benign ovarian tumor group and the healthy control group (P<0 .01) .Serum concentration in the stage Ⅲ - Ⅳwere higher than that in the stage Ⅰ - Ⅱ(P<0 .01) .In the combined detection of HE4 and CA125 ,the sensitivity ,specificity and accuracy for diag-nosing ovarian cancer were 84 .6% ,83 .9% and 89 .4% respectively .Their sensitivity and accuracy were higher than those of any single marker detection ,the specificity was consistent with that in the single CA 125 detection .Conclusion The combined detection of serum CA125 and HE4 is conducive to increase the diagnosis efficiency and has certain application value in the differential diag-nosis of benign and malignant ovarian tumor .